Upon disclosing the completion of one licensing deal for a migraine drug, Endo Pharmaceuticals Inc. said it has entered another - the second, an agreement for development and marketing rights to a breakthrough cancer pain product. (BioWorld Today)

Replidyne Inc. closed its largest financing, a $40 million second round, and concurrently in-licensed a late-stage compound to treat bacterial infections. (BioWorld Today)

DOV Pharmaceutical Inc. licensed worldwide rights of its triple uptake inhibitor compounds for psychiatric disorders to Merck & Co. Inc. in a deal worth $455 million, if all milestones are met. (BioWorld Today)